Disc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) Current ratio
Disc Medicine, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 24.1×, up 2.2× from fiscal 2025 (21.9×). Over the past ten years it has ranged from 0.2× (fiscal 2020) to 21.9× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 21.9× | 3.63% |
| FY2024 | 21.2× | 24.13% |
| FY2023 | 17.1× | 94.01% |
| FY2022 | 8.8× | 0.00% |
| FY2022 | 8.8× | 30.43% |
| FY2021 | 6.7× | 0.00% |
| FY2021 | 6.7× | 3,210.66% |
| FY2020 | 0.2× | 0.00% |
| FY2020 | 0.2× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 24.1× | 0.56% |
| Mar 2026 | 24.0× | 9.40% |
| Dec 2025 | 21.9× | (6.44%) |
| Sep 2025 | 23.5× | (26.96%) |
| 21 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| TNGX Tango Therapeutics, Inc. compare | 50.8× |
| IRON Disc Medicine, Inc. | 24.1× |
| XENE Xenon Pharmaceuticals Inc. compare | 21.0× |
| RLAY Relay Therapeutics, Inc. compare | 18.3× |
| PBLS Parabilis Medicines, Inc. compare | 17.9× |
| DYN Dyne Therapeutics, Inc. compare | 12.0× |
| VKTX Viking Therapeutics, Inc. compare | 7.3× |
| IOVA Iovance Biotherapeutics, Inc. compare | 5.2× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 3.8× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)